Link between Alzheimer's disease and traumatic brain damage clarified
This week scientists of the Flanders Interuniversity Institute for biotechnology (VIB) will once again publish a breakthrough in their research regarding Alzheimer's disease. The researchers, this time connected to the Catholic University of Leuven, discovered the function of one of the most important proteins related to Alzheimer's disease. They have indicated that the protein stimulates the growth of nerve paths in the brain, which is essential for recovery after brain damage. The results are published in EMBO Journal.
The normal function of the amyloidal precursor protein or APP clarified
It has been known for several years that APP is relevant in Alzheimer's disease. APP is the precursor of the amyloidal-β protein that causes the typical 'plaques' in the brains of patients. The normal function of APP was, however, not known. Maarten Leyssen and his colleagues have indicated that APP stimulates the development of nerve paths. Intact nerve paths are essential for the proper functioning of the brain. These connections can be damaged after traumatic brain damage resulting in the improper functioning of the brain. APP is responsible for stimulating the development of new nerve paths.
APP and Alzheimer's disease
These results also aid better understanding of certain aspects of Alzheimer's disease, where APP plays a major role. The fruit fly - an ideal model to study the brain's action - indicates that APP increases considerably after brain damage, namely in areas where new nerve paths need to be formed. Because more APP is made, more plaques can develop in the brain, a typical symptom of Alzheimer's disease. For the first time the results of VIB researchers explain the strong link between brain damage and Alzheimer's disease: not only do patients with major brain damage have more chance of developing Alzheimer's disease later on in life, their brains also often show plaques that strongly resemble those of Alzheimer patients.
Most read news
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.